349-354
Review
Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer
Muhammad Wasif Saif and Shahrukh Hashmi
355-363
Original Article
A novel N-alkylated prodigiosin analogue induced death in tumour cell through apoptosis or necrosis depending upon the cell type
Amit A. Deorukhkar, Ramesh Chander, Ruchi Pandey and Krishna B. Sainis
365-376
Original Article
Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL
Amrita V. Kamath, Jian Wang, Francis Y. Lee and Punit H. Marathe
377-393
Original Article
Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies
Andrew Evans, Victoria Bates, Helen Troy, Stephen Hewitt and Susan Holbeck, et al.
395-405
Original Article
A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging
C. Bornmann, R. Graeser, N. Esser, V. Ziroli and P. Jantscheff, et al.
407-413
Original Article
Abrogation of ionizing radiation-induced G2 checkpoint and inhibition of nuclear export by Cryptocarya pyrones
Christopher M. Sturgeon, Bruno Cinel, Ana R. Díaz-Marrero, Lianne M. McHardy and Michelle Ngo, et al.
415-421
Original Article
Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer
Bernard Royer, Delphine Delroeux, Emmanuel Guardiola, Marielle Combe and Guillaume Hoizey, et al.
423-433
Original Article
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors
Antonio Jimeno, Michelle A. Rudek, Thomas Purcell, Daniel A. Laheru and Wells A. Messersmith, et al.
435-441
Original Article
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma
Robert J. Jones, Robert E. Hawkins, Martin M. Eatock, David R. Ferry and Ferry A. L. M. Eskens, et al.
443-451
Original Article
Vascular activity of two silicon compounds, ALIS 409 and ALIS 421, novel multidrug-resistance reverting agents in cancer cells
Fabio Fusi, Antonella Ferrara, Attila Zalatnai, Joseph Molnar and Giampietro Sgaragli, et al.
453-458
Original Article
A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer
Ramesh K. Ramanathan, Joel Picus, Haralambos Raftopoulos, Stephen Bernard and A. Craig Lockhart, et al.
459-469
Original Article
Oligo-microarray analysis reveals the role of cyclophilin A in drug resistance
Shuai Chen, Mingjun Zhang, Honghui Ma, Hexige Saiyin and Suqin Shen, et al.
471-479
Original Article
Effect of cortisol on cell proliferation and the expression of lipoprotein lipase and vascular endothelial growth factor in a human osteosarcoma cell line
Kenshi Sakayama, Naohiko Mashima, Teruki Kidani, Tatsuhiko Miyazaki and Haruyasu Yamamoto, et al.
481-488
Original Article
Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene
Ricardo Bellott, Valérie Le Morvan, Virginie Charasson, Armelle Laurand and Marthe Colotte, et al.
489-496
Original Article
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors
Noboru Yamamoto, Atsushi Horiike, Yasuhito Fujisaka, Haruyasu Murakami and Tatsu Shimoyama, et al.
497-502
Original Article
Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide
Francisco Chung, Jenny Liu, Lai-Ming Ching and Bruce C. Baguley
503-508
Original Article
Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer
Fumiyoshi Ohyanagi, Atsushi Horiike, Yoshio Okano, Yukitoshi Satoh and Sakae Okumura, et al.
509-514
Original Article
A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial
Daigo Yamamoto, Satoru Iwase, Kaoru Kitamura, Hiroki Odagiri and Chizuko Yamamoto, et al.
515-524
Original Article
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period
Carolyn D. Britten, Fairooz Kabbinavar, J. Randolph Hecht, Carlo L. Bello and Jim Li, et al.
525-534
Original Article
A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells
Jiannong Li, Jean Viallet and Eric B. Haura